Virbac SA VIRP
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- €351.00
- Day Range
- €352.00–356.00
- 52-Week Range
- €297.00–389.50
- Bid/Ask
- €352.50 / €354.00
- Shares Outstanding
- 8.38M
- Market Cap
- €2.96B
- Volume/Avg
- 169 / 5,352
Key Statistics
- Price/Earnings (Normalized)
- 18.42
- Price/Sales
- 1.97
- Dividend Yield (Trailing)
- 0.41%
- Dividend Yield (Forward)
- 0.41%
- Dividend Payment Schedule
- Jul
- Total Yield
- 0.41%
Company Profile
Virbac SA is a drug manufacturing company with a focus on animal health. The company generates the vast majority of its revenue in Europe, and it also has its presence in Europe, North America, Far East Asia, India, Africa & Middle East (IMEA), Pacific, and Latin America.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Stock Style Box
- Mid Core
- Total Number of Employees
- 50
- Website
- https://www.virbac.com
Valuation
Metric | VIRP |
|---|---|
Price/Earnings (Normalized) | 18.42 |
Price/Book Value | 2.42 |
Price/Sales | 1.97 |
Price/Cash Flow | 13.14 |
Price/Earnings
VIRP
Financial Strength
Metric | VIRP |
|---|---|
Quick Ratio | 0.93 |
Current Ratio | 1.77 |
Interest Coverage | 28.09 |
Quick Ratio
VIRP
Profitability
Metric | VIRP |
|---|---|
Return on Assets (Normalized) | 8.36% |
Return on Equity (Normalized) | 14.26% |
Return on Invested Capital (Normalized) | 11.27% |
Return on Assets
VIRP
Drug Manufacturers - General Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Eli Lilly and Co LLY | LOCK|n#%WjQY | LOCK|Pr | $1T | |||
| Johnson & Johnson JNJ | LOCK|#V?<xg@ | LOCK|D#! | $671B | |||
| AbbVie Inc ABBV | LOCK|>%@?yv | LOCK|&&< | $518B | |||
| Roche Holding AG ADR RHHBY | LOCK|@^#pqtB | LOCK|?L | $386B | |||
| Merck & Co Inc MRK | LOCK|Mww<C& | LOCK|#MR | $353B | |||
| Novartis AG ADR NVS | LOCK|#^^$>Qy | LOCK|CFs | $300B | |||
| AstraZeneca PLC AZN | LOCK|ys?P>fQ | LOCK|J# | $282B | |||
| Amgen Inc AMGN | LOCK|%XLH#Ds | LOCK|Dy | $248B | |||
| Gilead Sciences Inc GILD | LOCK|%#R@?^ | LOCK|Qh# | $211B | |||
| Novo Nordisk AS ADR NVO | LOCK|$$Q^h& | LOCK|w?! | $179B |